Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and On-Demand Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT00772915Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Progression-free Survival Rate at 1 Year. Started Dec 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00772915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772915.